DA
NKTR icon

DCF Advisers’s Nektar Therapeutics NKTR Stock Holding History

DCF Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$81K – 83
2022
Q1 		$81K Sell
1,000
-1,087
-52% -$161K 0.04% 66
2021
Q4 		$423K Hold
2,087
– – 0.17% 60
2021
Q3 		$562K Hold
2,087
– – 0.25% 62
2021
Q2 		$537K Hold
2,087
– – 0.19% 66
2021
Q1 		$626K Hold
2,087
– – 0.27% 67
2020
Q4 		$532K Sell
2,087
-33
-2% -$8.53K 0.22% 66
2020
Q3 		$528K Sell
2,120
-747
-26% -$235K 0.27% 58
2020
Q2 		$996K Hold
2,867
– – 0.56% 40
2020
Q1 		$768K Hold
2,867
– – 0.5% 36
2019
Q4 		$928K Buy
+2,867
New +$831K 0.59% 39

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

DCF Advisers's NKTR Position: Q2 2022 in Review

DCF Advisers sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 1,000 shares — an estimated $81K sold.

DCF Advisers first reported a position in NKTR in Q4 2019 and held it in 10 quarters. The position peaked at $996K in Q2 2020. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • DCF Advisers reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • DCF Advisers sold 1,000 Nektar Therapeutics shares in Q2 2022, an estimated $81K.
  • DCF Advisers first reported a position in Nektar Therapeutics in Q4 2019 and held it in 10 quarters.
  • DCF Advisers's Nektar Therapeutics position peaked at $996K in Q2 2020.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on DCF Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.